Dr. Mishra earned his medical doctor degree from the Maharashtra University of Health Sciences, India, in 2005. After Internship and initial housemanship in Neurology, he received Swiss Federal Commission’s ESKAS Fellowship to train at the University Hospital of Lausanne (CHUV) from 2006 to 2008. At CHUV, he managed patients in stroke and behavioral neurology clinics and also conducted clinical research about the behavioral manifestations of acute stroke (e.g. neglect syndromes). Next, he went to the University of Glasgow, Scotland, and earned a PhD in 2012. For his PhD, he studied the use of i.v. alteplase in acute ischemic stroke patients who were recommended for exclusion as per the European drug authority, EMEA. Dr. Mishra’s doctoral work made significant contributions to the field informing whether the exclusion criteria proposed by the drug authorities were meaningful and should be followed. Between 2012 and 2014, he was at Stanford University for post doctoral work in Vascular Neurology. At Stanford, he studied the brain imaging profiles of ischemic stroke patients which are associated with improved outcomes after receiving reperfusion stroke therapy in extended time window. Subsequently, and after a year at the US FDA, he began his US clinical training, first at Tulane University from 2016 to 2018 and then moved to Icahn School of Medicine at Mount Sinai. At Mount Sinai Hospital and as a Levy Leon Fellow in the PGY4 year, he will undertake diffusion tractography of 7Tesla MRI data to investigate the integrity of the neural tracts arising from the epileptogenic foci in drug resistant epilepsy patients. His goal is to determine the optimal extent of surgical resection or fiber disconnection in drug resistant epilepsy.
